MIRA INFORM REPORT

Report Date :

26.03.2007

IDENTIFICATION DETAILS

Name :	MUNAWAR PHARMA (PRIVATE) LIMITED

Registered Office :	224-A, New Muslim Town, Lahore

Country :	Pakistan

Date of Incorporation :	1992

Com. Reg. No.:	00005622

Legal Form :	Private Limited Company

Line of Business :	Manufacture of Pharmaceutical Products.

RATING & COMMENTS

MIRA’s Rating :

RATING		STATUS	PROPOSED CREDIT LINE
41-55	Ba	Overall operation is considered normal. Capable to meet normal commitments.	Satisfactory

Status :	Satisfactory

Payment Behaviour :	Usually correct

Litigation :	Clear

Business Name

MUNAWAR PHARMA (PRIVATE) LIMITED

Full Address

Registered Address (New)

224-A, New Muslim Town, Lahore, Pakistan

Tel	92 (42) 5841327
Fax	92 (42) 5841328
Email	mpharm@wol.net.pk

Note:

The Registered Address of the company has been changed from “24,Circular Road, Outside Lahori Gate, Lahore” to “224-A, New Muslim Town, Lahore, Pakistan”.

Factory Location

Address	31 KM, Ferozepur Road, Lahore, Pakistan
Tel #	92 (42) 5270973, 5270974
Fax #	92 (42) 5272566

Short Description of Business

Nature of Business	Manufacture of Pharmaceutical Products.
Year Established	1992
Registration #	00005622

Legal Status

Subject Company was established as a Private Limited Company in 1992

Auditors

Aslam Khan & Co.

(Chartered Accountants)

11-Happy Home, 38/A Main Gulberg, Salman Ahmad Road, Lahore, Pakistan

Authorised Capital	Rs. 40,000,000/- Divided into 400,000 shares of Rs.100/- each
Issued & Paid up Capital	Rs. 15,300,000/- Divided into 153,000 shares of Rs. 100/- each

Details of Directors

Names

Nationality

Residential Address

Designation

Mr. Mohammad Arshad Sheikh

Mr. Sheikh Muhammad Rafi

Mr. Javed Iqbal Sheikh

Mr. Imran Arshad

Mr. Naveed Ahmad

Mr. Adnan Arshad

Mr. Muhammad Waqas

Pakistani

H. No. 3 Gulam Nabi Colony, Samanabad, Lahore

H. No.2 Gulam Nabi Colony, Samanabad, Lahore

H. No. 51-S, 22-B/3, Jinnah Colony, Samanabad, Lahore

H. No. 51-S, 22 B/3, Jinnah Colny, Samanabad, Lahore

H. No. 3 Gulam Nabi Colony, Samanabad, Lahore

Chief

Executive

Director

Note:

The Change of Chief Executive as well as directors was made during 2006.

Shareholders

Names

Address

No of Shares

Waheed Ahmad

Sheikh Mohammed Rafi

Javaid Iqbal Sheikh

Muhammad Usman

Muhammad Waqas

Mst. Haleema Javaid

Imran Arshad

Naveed Ahmad

Wasim Ahmad

Mr. Mohammad Arshad Sheikh

Adnan Arshad

Muhammad Yousaf

Nadeem Ahmed

Arslan Waheed

Muhammad Shafique

H. No. 51-S, 22 B/3, Jinnah Colny, Samanabad, Lahore

H. No.2 Gulam Nabi Colony, Samanabad, Lahore

H. No. 3 Gulam Nabi Colony, Samanabad, Lahore

2 Gulam Nabi Colony, Samanabad, Lahore

H. No. 3 Gulam Nabi Colony, Samanabad, Lahore

H. No. 51-S, 22-B/3, Jinnah Colony, Samanabad, Lahore

H. No. 3 Gulam Nabi Colony, Samanabad, Lahore

H. No. 51-S, 22-B/3, Jinnah Colony, Samanabad, Lahore

H. No. 3 Gulam Nabi Colony, Samanabad, Lahore

2 Gulam Nabi Colony, Samanabad, Lahore

10,000

14,000

5,000

10,000

7,000

10,000

12,000

10,000

5,000

10,000

Associates

Subsidiary

None

Associated Companies

- Do -

Product/Services

Engaged in manufacture and sale of pharmaceutical products by their brand name of AMCOUGH, AMINOPHYLLINE, AMOXYCILLIN, AMPLOX, ANALVON, ASCORBIC ACID, ASPIRIN, CANDICAN, CEFITOL, CEFITOL FORTE, CEPHRIDE, CHLOROQUINE PHOSPHATE, CHLORPHENIRAMINE, CLOCIL FORTE, DEXAMED, DEXAMETHASONE, DIDOMET, DIMEN, DIMENTIN, EMITIN, ERYTHROMYCIN, FOSFOMYCIN, FUMOLIC, GASTROGEL, GLUBIRON, GLUBIRON F, HYLINE, HYOSCINE, HYOSCINE COMPOUND, IBUPROFEN, INDOMETHACIN, LAXIDE, LAXIL, LINCOMED, M-PHENICOL, M. CLOX, MANURAX, MENAMIC, METOCLOP, METRONIDAZOLE, MUANPOL, MUNOQUINE, MZOLE, MZOLIDONE, NAPLUR, OXYTETRACYCLINE, PARACETAMOL, PESPOLIN, PHENAMINE, PHENOBARBITONE, PHOLTUSS,THYRAXINIL, TRISEP, VIBREX, WORMATIN, ZAMID, ZEPOX, ZONATE

Annual Production Volume

The capacity and production of the company’s plant is indeterminable as it is multi-product and involves varying processes of manufacture.

Number of Employees

120 - 135

Annual Sales Volume

Year	In Pak Rupees
2005	180,000,000 (Estimated)

Agencies (Foreign)

ASHU INTERNATIONAL, INDIA.

SHOUGUANG FUKANG PHARMACEUTICAL CO. LTD, CHINA.

MANGALAM DRUGS & ORGANICS LIMITED, INDIA.

Bankers and their addresses

(1) Prime Commercial Bank Ltd., 19-Khayaban-e-Iqbal, Stock Exchange Building, Lahore, Pakistan.

(2) Prime Commercial Bank Limited, 61 – Main Boulevard, Gulberg, Lahore, Pakistan.

Foreign Exchange Rates

Currency	Unit	Pakistani Rupee
US Dollar	1	Rs. 60.75
UK Pound	1	Rs.118.80
Euro	1	Rs. 80.40

Membership on professional bodies

Lahore Chamber of Commerce & Industry. (LCCI)

Pakistan Pharmaceutical Manufacturers Association. (PPMA)

Comments

Subject Company was established in 1992 and is engaged in manufacture & marketing of pharmaceutical products. Their trade relations are reported as fair. Payment to creditors etc are reported as normal. The Company can be considered for normal business dealings at usual trade terms and conditions.

RATING EXPLANATIONS

RATING		STATUS	PROPOSED CREDIT LINE
>86	Aaa	Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums	Unlimited
71-85	Aa	Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums	Large
56-70	A	Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums	Fairly Large
41-55	Ba	Overall operation is considered normal. Capable to meet normal commitments.	Satisfactory
26-40	B	Unfavourable & favourable factors carry similar weight in credit consideration. Capability to overcome financial difficulties seems comparatively below average/normal.	Small
11-25	Ca	Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity	Limited with full security
<10	C	Absolute credit risk exists. Caution needed to be exercised	Credit not recommended
NR		In view of the lack of information, we have no basis upon which to recommend credit dealings	No Rating

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

Financial condition (40%) Ownership background (20%) Payment record (10%)

Credit history (10%) Market trend (10%) Operational size (10%)

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions